Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 26

Cited In for PubMed (Select 18632615)

1.

Consequence of the tumor-associated conversion to cyclin D1b.

Augello MA, Berman-Booty LD, Carr R 3rd, Yoshida A, Dean JL, Schiewer MJ, Feng FY, Tomlins SA, Gao E, Koch WJ, Benovic JL, Diehl JA, Knudsen KE.

EMBO Mol Med. 2015 Mar 18;7(5):628-47. doi: 10.15252/emmm.201404242.

2.

Palbociclib: an evidence-based review of its potential in the treatment of breast cancer.

Cadoo KA, Gucalp A, Traina TA.

Breast Cancer (Dove Med Press). 2014 Aug 4;6:123-33. doi: 10.2147/BCTT.S46725. eCollection 2014. Review.

3.

Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer.

Zhao M, Ramaswamy B.

World J Clin Oncol. 2014 Aug 10;5(3):248-62. doi: 10.5306/wjco.v5.i3.248. Review.

4.

Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy.

Zhou Z, Qiao JX, Shetty A, Wu G, Huang Y, Davidson NE, Wan Y.

Cell Mol Life Sci. 2014 Apr;71(8):1549. doi: 10.1007/s00018-013-1376-3. Retraction in: Cell Mol Life Sci. 2014 Apr;71(8):1549.

5.

AR function in promoting metastatic prostate cancer.

Augello MA, Den RB, Knudsen KE.

Cancer Metastasis Rev. 2014 Sep;33(2-3):399-411. doi: 10.1007/s10555-013-9471-3. Review.

PMID:
24425228
6.

RNA splicing: a new player in the DNA damage response.

Lenzken SC, Loffreda A, Barabino SM.

Int J Cell Biol. 2013;2013:153634. doi: 10.1155/2013/153634. Epub 2013 Sep 12. Review.

7.

Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes.

Augello MA, Burd CJ, Birbe R, McNair C, Ertel A, Magee MS, Frigo DE, Wilder-Romans K, Shilkrut M, Han S, Jernigan DL, Dean JL, Fatatis A, McDonnell DP, Visakorpi T, Feng FY, Knudsen KE.

J Clin Invest. 2013 Jan;123(1):493-508. doi: 10.1172/JCI64750. Epub 2012 Dec 21.

8.

Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer.

Myklebust MP, Li Z, Tran TH, Rui H, Knudsen ES, Elsaleh H, Fluge Ø, Vonen B, Myrvold HE, Leh S, Tveit KM, Pestell RG, Dahl O.

Br J Cancer. 2012 Nov 6;107(10):1684-91. doi: 10.1038/bjc.2012.463. Epub 2012 Oct 25.

9.

Regulation of chemoresistance via alternative messenger RNA splicing.

Eblen ST.

Biochem Pharmacol. 2012 Apr 15;83(8):1063-72. doi: 10.1016/j.bcp.2011.12.041. Epub 2012 Jan 8. Review.

10.

Mechanisms and consequences of alternative polyadenylation.

Di Giammartino DC, Nishida K, Manley JL.

Mol Cell. 2011 Sep 16;43(6):853-66. doi: 10.1016/j.molcel.2011.08.017. Review.

11.

Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged.

David CJ, Manley JL.

Genes Dev. 2010 Nov 1;24(21):2343-64. doi: 10.1101/gad.1973010. Review.

12.

An emerging role for nuclear RNA-mediated responses to genotoxic stress.

Busà R, Sette C.

RNA Biol. 2010 Jul-Aug;7(4):390-6. Epub 2010 Jul 1.

13.

Cyclin D1b in human breast carcinoma and coexpression with cyclin D1a is associated with poor outcome.

Abramson VG, Troxel AB, Feldman M, Mies C, Wang Y, Sherman L, McNally S, Diehl A, Demichele A.

Anticancer Res. 2010 Apr;30(4):1279-85.

14.

Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene.

Olshavsky NA, Comstock CE, Schiewer MJ, Augello MA, Hyslop T, Sette C, Zhang J, Parysek LM, Knudsen KE.

Cancer Res. 2010 May 15;70(10):3975-84. doi: 10.1158/0008-5472.CAN-09-3468. Epub 2010 May 11.

15.

Cyclin K and cyclin D1b are oncogenic in myeloma cells.

Marsaud V, Tchakarska G, Andrieux G, Liu JM, Dembele D, Jost B, Wdzieczak-Bakala J, Renoir JM, Sola B.

Mol Cancer. 2010 May 10;9:103. doi: 10.1186/1476-4598-9-103.

16.

Cyclin D1 regulates hepatic estrogen and androgen metabolism.

Mullany LK, Hanse EA, Romano A, Blomquist CH, Mason JI, Delvoux B, Anttila C, Albrecht JH.

Am J Physiol Gastrointest Liver Physiol. 2010 Jun;298(6):G884-95. doi: 10.1152/ajpgi.00471.2009. Epub 2010 Mar 25.

17.

FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance.

Millour J, Constantinidou D, Stavropoulou AV, Wilson MS, Myatt SS, Kwok JM, Sivanandan K, Coombes RC, Medema RH, Hartman J, Lykkesfeldt AE, Lam EW.

Oncogene. 2010 May 20;29(20):2983-95. doi: 10.1038/onc.2010.47. Epub 2010 Mar 8.

18.

Regulation of hormonal therapy resistance by cell cycle machinery.

Nair BC, Vadlamudi RK.

Gene Ther Mol Biol. 2008 Jan 1;12:395.

19.

Targeting the RB-pathway in cancer therapy.

Knudsen ES, Wang JY.

Clin Cancer Res. 2010 Feb 15;16(4):1094-9. doi: 10.1158/1078-0432.CCR-09-0787. Epub 2010 Feb 9.

20.

Genotoxic stress causes the accumulation of the splicing regulator Sam68 in nuclear foci of transcriptionally active chromatin.

Busà R, Geremia R, Sette C.

Nucleic Acids Res. 2010 May;38(9):3005-18. doi: 10.1093/nar/gkq004. Epub 2010 Jan 27.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk